经鼻高流量氧疗与常规氧疗对重症COVID-19患者有创机械通气需求及临床恢复的影响:一项随机临床试验
这项在哥伦比亚3家医院急诊和ICU开展的随机、开放标签临床试验,纳入220例因COVID-19导致呼吸窘迫且PaO₂/FiO₂<200的成人患者,随机接受经鼻高流量氧疗(n=109)或常规氧疗(n=111)。主要终点中,高流量组插管34例(34.3%)vs 常规组51例(51.0%)(HR 0.62;95%CI 0.39-0.96;P=.03);28天内中位临床恢复时间高流量组11天(IQR 9-14)vs 常规组14天(IQR 11-19)(HR 1.39;95%CI 1.00-1.92;P=.047)。作者结论认为,在重症COVID-19患者中,经鼻高流量氧疗较常规低流量氧疗显著减少机械通气需求并缩短临床恢复时间。
要点
- 重症COVID-19且PaO₂/FiO₂<200的成人,经鼻高流量氧疗组插管率34.3%(34例)vs 常规氧疗组51.0%(51例),HR 0.62(95%CI 0.39-0.96;P=.03)。
- 28天内中位临床恢复时间:高流量组11天(IQR 9-14)vs 常规组14天(IQR 11-19),HR 1.39(95%CI 1.00-1.92;P=.047)。
- 疑似细菌性肺炎高流量组13例(13.1%)vs 常规组17例(17.0%);菌血症分别为7例(7.1%)vs 11例(11.0%)。
- 研究在3家医院的急诊和ICU开展,纳入标准为呼吸窘迫且PaO₂/FiO₂<200的COVID-19成人患者。
适用人群与场景
- 因COVID-19导致呼吸窘迫、动脉血氧分压与吸入氧浓度比值(PaO₂/FiO₂)<200的成人患者,场景为急诊和ICU(哥伦比亚3家医院)。
诊断标准与关键阈值
- 纳入标准:呼吸窘迫且PaO₂/FiO₂<200的COVID-19成人患者。
处置流程与药物剂量
- 经鼻高流量氧疗组(n=109):通过鼻导管给予高流量氧疗。
- 常规氧疗组(n=111):给予常规低流量氧疗。
研究设计与关键结果
- 随机、开放标签临床试验,在哥伦比亚3家医院的急诊和ICU开展,2020年8月至2021年1月随机220例成人,末次随访2021年2月10日;高流量氧疗组n=109,常规氧疗组n=111。
- 分析纳入199例(中位年龄60岁;女性65例[32.7%]);高流量组插管34例(34.3%)vs 常规组51例(51.0%),HR 0.62(95%CI 0.39-0.96;P=.03)。
- 28天内中位临床恢复时间:高流量组11天(IQR 9-14)vs 常规组14天(IQR 11-19),HR 1.39(95%CI 1.00-1.92;P=.047);恢复采用7分类序贯量表(范围1-7,评分越高病情越重)评估。
- 疑似细菌性肺炎:高流量组13例(13.1%)vs 常规组17例(17.0%);菌血症:高流量组7例(7.1%)vs 常规组11例(11.0%)。
- 效应采用Cox比例风险模型计算,校正低氧血症严重程度、年龄和合并症。
证据类型、等级与局限
- 证据类型:随机、开放标签临床试验(RCT);试验注册号NCT04609462。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在重症COVID-19患者中,经鼻高流量氧疗较常规低流量氧疗显著减少机械通气需求并缩短临床恢复时间。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effect of high-flow oxygen therapy vs conventional oxygen therapy has not been established in the setting of severe COVID-19.
OBJECTIVE: To determine the effect of high-flow oxygen therapy through a nasal cannula compared with conventional oxygen therapy on need for endotracheal intubation and clinical recovery in severe COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label clinical trial conducted in emergency and intensive care units in 3 hospitals in Colombia. A total of 220 adults with respiratory distress and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of less than 200 due to COVID-19 were randomized from August 2020 to January 2021, with last follow-up on February 10, 2021.
INTERVENTIONS: Patients were randomly assigned to receive high-flow oxygen through a nasal cannula (n = 109) or conventional oxygen therapy (n = 111).
MAIN OUTCOMES AND MEASURES: The co-primary outcomes were need for intubation and time to clinical recovery until day 28 as assessed by a 7-category ordinal scale (range, 1-7, with higher scores indicating a worse condition). Effects of treatments were calculated with a Cox proportional hazards model adjusted for hypoxemia severity, age, and comorbidities.
RESULTS: Among 220 randomized patients, 199 were included in the analysis (median age, 60 years; n = 65 women [32.7%]). Intubation occurred in 34 (34.3%) randomized to high-flow oxygen therapy and in 51 (51.0%) randomized to conventional oxygen therapy (hazard ratio, 0.62; 95% CI, 0.39-0.96; P = .03). The median time to clinical recovery within 28 days was 11 (IQR, 9-14) days in patients randomized to high-flow oxygen therapy vs 14 (IQR, 11-19) days in those randomized to conventional oxygen therapy (hazard ratio, 1.39; 95% CI, 1.00-1.92; P = .047). Suspected bacterial pneumonia occurred in 13 patients (13.1%) randomized to high-flow oxygen and in 17 (17.0%) of those randomized to conventional oxygen therapy, while bacteremia was detected in 7 (7.1%) vs 11 (11.0%), respectively.
CONCLUSIONS AND RELEVANCE: Among patients with severe COVID-19, use of high-flow oxygen through a nasal cannula significantly decreased need for mechanical ventilation support and time to clinical recovery compared with conventional low-flow oxygen therapy.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04609462.
参考来源
- Ospina-Tascón GA, Calderón-Tapia LE, García AF, et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 34874419. doi:10.1001/jama.2021.20714
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。